featured
Nemolizumab Plus Topical Agents Improve Moderate-to-Severe Pruritis in Patients With Atopic Dermatitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The British Journal of Dermatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Nemolizumab plus topical agents in patients with atopic dermatitis (AD) and moderate-to-severe pruritus provide improvement in pruritus and signs of AD for up to 68 weeks: results from two phase III, long-term studies
Br J Dermatol 2021 Nov 02;[EPub Ahead of Print], K Kabashima, T Matsumura, H Komazaki, M KawashimaFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.